In a recent turn of events, the Ministry of Health and Family Welfare has come forward to debunk false and misleading media reports regarding a significant hike in medicine prices. According to the ministry, these reports are not only inaccurate but also malicious in nature, spreading misinformation among the public.
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, plays a crucial role in regulating medicine prices in India. Annually, the NPPA revises the ceiling prices of scheduled medicines based on the Wholesale Price Index (WPI). This year, the WPI increase stands at a mere (+) 0.00551%, which has led to no change in the prevailing ceiling prices for 782 medicines. Additionally, 54 medicines will see a marginal increase of just Rs. 0.01 (one paisa) in their ceiling prices.
It is important to understand that the WPI increase is the maximum permissible as per the Drug Price Control Orders (DPCO) 2013. Manufacturers have the discretion to avail or not avail of this increase based on market dynamics. This means that despite the WPI increase, there will be almost no change in the ceiling price of medicines for the fiscal year 2024-25.
The ministry’s clarification aims to reassure the public that there will be no significant hike in medicine prices. The revised prices, applicable from 1st April 2024, can be viewed on the NPPA’s website. It is also important to note that for non-scheduled formulations, manufacturers have the liberty to fix prices. However, no manufacturer can increase the Maximum Retail Price (MRP) by more than 10% during the preceding 12 months under the DPCO 2013.
This clarification comes at a crucial time when affordable healthcare is a top priority for the government. The ministry remains committed to ensuring that essential medicines remain accessible and affordable for all. It also serves as a reminder to the public to verify information from credible sources before believing in sensationalized media reports.
In conclusion, the Ministry of Health and Family Welfare’s clarification on the medicine price hike claims is a testament to its commitment to transparency and accountability. It sends a strong message that misinformation will not be tolerated, especially when it comes to vital aspects of public health.
